Watson Pharmaceuticals unit receives FDA approval of generic Sanctura XR Watson Pharmaceuticals (WPI) announced that its subsidiary Watson Laboratories-Florida has received approval from the U.S. FDA on its Abbreviated New Drug Application for Trospium Chloride Extended-release Capsules, the generic equivalent to Allergan's (AGN) Sanctura XR. Watson intends to begin shipping the product immediately. Sanctura XR is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. For the 12 months ending July 31, Sanctura XR had total U.S. sales of approximately $67M according to IMS Health data.
News For WPI;AGN From The Last 14 Days
Check below for free stories on WPI;AGN the last two weeks.
On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital.
Subscribe for More Information